Concepedia

Toshiyuki Kozuki

TK

Statistics

Publications

72

Citations

5.3K

H-Index

32

Active since

2004

Affiliations

Shikoku Cancer Center(Current)

Okayama University Hospital

Okayama University

Aichi Cancer Center

National Hospital Organization

Toshiyuki Kozuki is an author at Shikoku Cancer Center specializing in medicine, oncology, and lung cancer.

ORCID

Top concepts

Publications per year

2004–2025

72

Publications

72

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 895 citations

, , +8

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Thoracic Oncology · 2020 · 587 citations · Full text

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Clinical Oncology · 2018 · 220 citations

, , +16

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh et al. · The Lancet Oncology · 2020 · 203 citations

, , +5

1–5 of 72